<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377478</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17040272</org_study_id>
    <nct_id>NCT03377478</nct_id>
  </id_info>
  <brief_title>Expanding the Pool in Lung Transplantation</brief_title>
  <official_title>Expanding the Pool in Lung Transplantation: The Use of Hepatitis C Positive Donor Lungs in Hepatitis C Negative Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To perform a study (100 patients) utilizing Hepatitis C positive (HCV Ab+/NAT -) donor lungs
      for hepatitis C negative recipients with post-operative surveillance and treatment only if a
      recipient infection occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a proof of concept study in which positive donors will be
      used for HCV negative patients. Following lung transplantation patients will undergo HCV
      antibody, virus PCR, and liver function testing. Recipients whom test positive for HCV
      viremia for 2 consecutive tests at any point will complete 12 weeks of Sofosbuvir/velpatasvir
      therapy.

      This initial study would enroll 100 patients and utilize donors that are young, otherwise
      healthy whom are Hepatitis C antibody positive but Nucleic Acid Amplification Testing (NAT)
      negative (HCV Ab+/NAT-). The recipients would be limited to those patients who have
      previously consented to receive a high risk lung transplant, consented to participant in this
      study, and who are physiologically optimized for transplantation (e.g., low risk for lung
      transplantation).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Viremia</measure>
    <time_frame>at 2 years</time_frame>
    <description>Incidence of HCV Viremia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>at 2 years</time_frame>
    <description>Rate of HCV seroconversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Testing</measure>
    <time_frame>at 2 years</time_frame>
    <description>Assessment of Hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>at 2 years</time_frame>
    <description>Survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>at 2 years</time_frame>
    <description>The incidence of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waitlist</measure>
    <time_frame>at 2 years</time_frame>
    <description>Time on waitlist will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatits C</condition>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>Lung Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.</description>
    <arm_group_label>Lung Transplant</arm_group_label>
    <other_name>Procedure</other_name>
    <other_name>Sofosbuvir/velpatasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who sign the informed consent for this study

          -  Patients whom agree to receive a PHS high risk organ

          -  Patients listed for heart transplantation

          -  Age 18-65

        Exclusion Criteria:

          -  Patients who do not sign informed consent for this study

          -  HIV Seropositivity

          -  HBV Seropositivity (HBcAb and/or HBsAg positive)

          -  Abnormal liver enzymes - 3 times the normal liver function values (Bilirubin, INR,
             AST, ALT)

          -  Acute or chronic renal insufficiency (creatinine clearance &lt;50 ml/min) or history of
             dialysis

          -  Patients on ECMO

          -  Respiratory insufficiency requiring mechanical respiratory support (ventilator, BiPAP)

          -  Liver insufficiency

          -  Prior history of hepatitis C

          -  Allergy to Sofosbuvir/velpatasvir

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan D'Cunha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Surgery/University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan D'Cunha, MD, PhD</last_name>
    <phone>412-648-6315</phone>
    <email>dcunhaj@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pablo Sanchez, MD</last_name>
    <phone>412-648-6315</phone>
    <email>sanchezpg@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan D'Cunha, MD, PhD</last_name>
      <phone>412-648-6315</phone>
      <email>dcunhaj@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Sanchez, MD</last_name>
      <phone>412-648-6315</phone>
      <email>sanchezpg@upmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/Sofosbuvir</url>
    <description>Sofosbuvir</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>Drug Information</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jonathan D'Cunha</investigator_full_name>
    <investigator_title>Associate Professor of Cardiothoracic Surgery; Chief, Division of Lung Transplantation/Lung Failure</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

